Clinical Trials · NCT06010004
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 401
- Start date
- Sep 2023
- Locations
- 40 sites, Japan
- Primary endpoint
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)